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‧DNA binding protein (DBP) was designed to raise site-selectivity of phiC31 integrase. 
‧DBP has two DNA binding motif to tether the donor vector to the target sequence. 
‧DBP did not affect integration efficiency of phiC31 integrase in human cells. 
‧DBP enhanced integration site-selectivity of phiC31 integrase up to 26-fold. 
‧Delayed expression of integrase after that of DBP leading to higher site-selectivity. 
Abstract 1 
 2 
PhiC31 integrase-based vectors can integrate therapeutic genes selectively into attP or 3 
pseudo-attP sites in genomes, but considerable numbers of pseudo-attP sites in human genomes exist 4 
inside endogenous gene-coding regions. To avoid endogenous gene disruptions, we aimed to enhance 5 
the integration site-specificity of the phiC31 integrase-based vector using a sequence-specific DNA-6 
binding protein containing Gal4 and LexA DNA-binding motifs. The dual DNA-binding protein was 7 
designed to tether the UAS-containing donor vector to the target sequence, the LexA operator, and 8 
restrict integration to sites close to the LexA operator. To analyze the site-specificity in chromosomal 9 
integration, a human cell line having LexA operators on the genome was established, and the cell line 10 
was transfected with donor vectors expressing the DNA-binding protein and the phiC31 integrase 11 
expression vector (helper vector). Quantitative PCR indicated that integration around the LexA 12 
operator was 26-fold higher with the UAS-containing donor vector than with the control. Sequence 13 
analysis confirmed that the integration occurred around the LexA operator. The dual DNA-binding 14 
protein-based targeted integration strategy developed herein would allow safer and more reliable 15 
genetic manipulations for various applications, including gene and cell therapies. 16 
 17 
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Chromosomal integration enables sustained transgene expression and cell division-3 
dependent replication of transgenes. Therefore, integrative vectors have often been applied to gene 4 
therapies (Calos, 2006), reprogramming (Takahashi and Yamanaka, 2006), induction of differentiation 5 
(Lacoste et al., 2009), tumor-model establishments (Carlson et al., 2005) and production of 6 
recombinant proteins (Tomita et al., 2003). PhiC31 integrase, a serine recombinase of Streptomyces 7 
phage, is widely used for chromosomal integration (Calos, 2006). In its natural context, phiC31 8 
integrase integrates phage genomes into bacterial genomes by recombination between phage attP sites 9 
and bacterial attB ones (Thorpe and Smith, 1998). PhiC31 integrase can also react with pseudo-attP 10 
sequences that partially match with bacterial attP sequences, and thereby integrate plasmid vectors 11 
containing attB sequences (called “donor vectors”) into the genomes of many organisms, including 12 
yeasts (Thomason et al., 2001), insects (Groth et al., 2004), amphibians (Allen and Weeks, 2005), birds 13 
(Leghton et al., 2008), and mammals, in both cultured cells (Groth et al., 2000 and Thyagarajan et al., 14 
2001) and adult animals (Olivares et al., 2002). Such attP or pseudo-attP-targeting characteristics of 15 
phiC31 integrase-based vector systems enable site-specific integration, unlike other integrative vectors 16 
including lentiviral vectors or Sleeping Beauty (Vink et al., 2009), piggyBac (Nakanishi et al., 2010 17 
and 2011), and Tol2 (Grabundzija et al., 2010) transposon-based vectors. Gene integration into or close 18 
to endogenous genes can disrupt or dysregulate their function, and sometimes induces severe adverse 19 
effects such as cancer (Hacein-Bey-Abina et al., 2003). In addition, random integration of sites results 20 
in a variegation of integrated transgene expression, which is called “position effect variegation” 21 
(Robertson et al., 1995). While some newer techniques, including transcription activator-like effector 22 
nucleases (TALENs) (Cermak et al., 2011 and Miller et al., 2011) and clustered regularly interspaced 23 
short palindromic repeats (CRISPR)/Cas9 (Cong et al., 2013 and Mali et al., 2013), are available for 24 
site-specific chromosomal integration, phiC31 integrase-based vector systems still remain useful 25 
because it allows in vivo gene integration in adult mammals (Olivares et al., 2002). However, phiC31 26 
integrase-based vector systems are not sufficient in terms of site-specificity of integration, considering 27 
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that the human genome has 202-764 pseudo-attP sequences, about 38.7% of which are associated with 1 
endogenous genes (Chalberg et al., 2006). 2 
In addition to the development of mutant integrases that have higher integration site-3 
specificity (Gersbach et al., 2010 and Keravala et al., 2009), utilization of sequence-specific DNA-4 
binding proteins might be a promising approach for enhancing the integration site-specificity of 5 
phiC31 integrase-based vectors. It could be more easily adapted to an arbitrary target sequence by 6 
customizing sequence-specific DNA-binding motifs such as zinc finger (Carroll et al., 2006, Mandell 7 
and Barbas 2006, Urnov et al., 2005, and Wright et al., 2006) or transcription activator-like effector 8 
(TALE) (Cermak et al., 2011, Miller et al., 2011, and Zhang et al., 2011). Enhanced site-specificity of 9 
integration due to fusion with DNA-binding proteins has been achieved with transposase (Ammar et 10 
al., 2012, Ivics et al., 2007, Kettlun et al., 2011, Lacoste et al., 2009, Maragathavally et al., 2006, 11 
Owens et al., 2012, Voigt et al., 2012, and Yant et al., 2007), retroviral integrase (Tan et al., 2004 and 12 
2006), Tn3 resolvase and Gin invertase (Gordley et al., 2009). However, it has also been suggested 13 
that the coupling of phiC31 integrase with the DNA-binding protein results in loss of activity 14 
(Shinohara et al., 2007). On the other hand, Ivics et al. (2007) proposed a conceptually different 15 
approach whereby a dual DNA-binding protein is utilized to tether the donor vector to the binding 16 
target in chromosomes and restricts the integration to nearby sites. They demonstrated that co-17 
transfection of cells with dual LexA/SAF-box (or LexA/TetR) DNA-binding proteins successfully 18 
enhanced the site-specificity of Sleeping Beauty transposase-mediated integration. We thought that 19 
this technique might be applicable to the phiC31 integrase-based vector system, since phiC31 integrase 20 
itself is in a native form. 21 
In this context, the present study aimed to further improve the site-specificity of a phiC31 22 
integrase-based vector system by combination with a dual DNA-binding protein. We made some 23 
modifications in the design of the donor vector as compared to the methods of Ivics et al. We developed 24 
a donor vector which carries both an attP sequence and the expression cassettes of a dual DNA-binding 25 
protein, so that we could ensure the expression of the DNA-binding protein and minimize the risk of 26 
nonspecific integration. In addition, to decrease the probability that phiC31 integrase-mediated 27 
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integration precedes the DNA-binding protein-mediated tethering, we transfected cells with the helper 1 
vector 1 or 2 days later than the donor vectors. These modifications allowed us to successfully increase 2 
the percentage of the targeted integration by 4.5-fold in the inter-plasmid integration assay and up to 3 
26-fold in the chromosomal integration assay. The present study is the first demonstration that 4 
sequence-specific DNA-binding proteins can limit the chromosomal integration due to phiC31 5 
integrase-based vectors to the more specific sites. 6 
 7 
Materials and Methods 8 
 9 
pDNA 10 
 KOD-plus ver.2 or KOD-plus Neo (Toyobo, Osaka, Japan) was used for PCRs to prepare 11 
inserts, and Rapid DNA Dephos & Ligation Kit (Roche Diagnostics, Tokyo, Japan) or Mighty Cloning 12 
Kit (blunt end) (Takara Bio, Otsu, Japan) was used for ligations. All pDNAs were amplified in the E. 13 
coli strains DH5α or HST08, isolated and purified using PureYield plasmid Miniprep Kit (Promega, 14 
Tokyo, Japan). For details of pDNA construction, see supplementary methods. 15 
 16 
Cell culture 17 
HEK293 and Hela cells were maintained in Dulbecco’s modified Eagle’s essential medium 18 
containing 10% fetal bovine serum. 19 
 20 
Establishment of a Hela-attPlex4R stable cell line 21 
Hela cells were transfected with pIR-attPlex4R and pFerH-PBTP using XtremeGene9 22 
(Roche Diagnostics). The transfected cells were selected by antibiotic G418 (Nacalai Tesque, Kyoto, 23 
Japan) over 2 weeks from day 2 onward, and cloned. To calculate the pIR-attPlex4R-derived 24 
transposons/endogenous RNaseP gene copy number, real-time PCR was performed with genomic 25 
DNA extracted from clone cells and digested with restriction enzymes BssHII and HindIII, using a 26 
Light-Cycler instrument (Roche Diagnostics) and SYBR Premix Ex Taq (Takara Bio). The sequences 27 
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of the primer sets used to determine the copy numbers of the neomycin-resistance gene in the 1 
transposon and endogenous RNaseP gene were CGGATGGAAGCCGGTCTTGTC + 2 
AGAAGGCGATAGAAGGCGATG and AGATTTGGACCTGCGAGCG + 3 
GAGCGGCTGTCTCCACAAGT, respectively. pVITRO1-neo-RNasePfragment digested with 4 
BssHII and HindIII that contained both the neomycin-resistance gene and a fragment of the RNaseP 5 
gene was used to generate a standard curve. 6 
 7 
Assay of Renilla luciferase activity 8 
HEK293 cells were seeded onto 6- or 12-well plates. Eighteen hours later, the cells were 9 
transfected with the indicated amount of pDNA using XtremeGene9 and then lyzed using lysis buffer 10 
(0.05% Triton X-100, 2 mM EDTA, 0.1 M Tris, pH7.8) at the indicated times. The Renilla luciferase 11 
activity of the cell lysate was measured using a Biolux Gaussia luciferase assay kit (New England 12 
BioLabs Japan, Tokyo, Japan) and Lumat LB 9507 (EG & G Berthold, Bad Wildbad, Germany). 13 
 14 
Colony-counting assay 15 
Hela cells (2.5×104 cells) were seeded onto 24-well plates, and 18 h later transfected with 16 
the indicated amount of DNA using XtremeGene9. Two days after transfection, the cells were 17 
harvested, and 10% or 90% of the cells were transferred to 6-well plates and maintained in medium 18 
containing 3 µg/ml blasticidin S (Invivogen) for two weeks. To count blasticidin-resistant colonies, 19 
cells were fixed with 4% paraformaldehyde in PBS (Wako Pure Chemical Industries, Osaka, Japan) 20 
for 10 min and stained with 0.2% methylene blue (Wako Pure Chemical Industries) in PBS. The 21 
numbers of colonies were corrected by the dilution ratio. 22 
 23 
Analysis of integration site-specificity in inter-plasmid integration 24 
Hela cells (6x105 cells) were transfected with 1 µg of pSV40-int, 125 ng of pAttP-lex1F, 1R, 25 
2F, 2R, 3F, 3R, 4F, 4R and 1 µg of pTargetB-NLS-Rluc or pTargetB-LexA-Rluc using XtremeGene9. 26 
Two days later, DNA was extracted from these cells using a Genelute mammalian genomic DNA 27 
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extraction kit (Sigma-Aldrich Japan, Tokyo, Japan). The extracted DNA was used to transform the E. 1 
coli strain DH5α or HST08. pDNA was purified from E. coli resistant to both kanamycin and 2 
blasticidin using a PureYield plasmid Miniprep Kit (Promega). Purified pDNA was digested with 3 
restriction enzymes either BamHI, NdeI, SpeI, BstZ17I plus NdeI. These digested pDNAs were 4 
electrophoresed on 1% agarose S (Nippon Gene, Tokyo, Japan) gel to determine which recipient 5 
vectors were integrated with donor vectors. 6 
 7 
Analysis of targeted chromosomal integration 8 
Hela-attPlex4R cells (5×104 cells) were seeded onto 6-well plates, and 18 hr later transfected 9 
with 500 ng of the donor vectors using XtremeGene9. One or two days after transfection of the donor 10 
vectors, the cells were transfected with 500 ng of pCMV-int. From three days after transfection of the 11 
donor vectors, the cells were maintained in medium containing 3 µg/ml blasticidin S for 18 days. After 12 
blasticidin selection, DNA was extracted from these cells using a Genelute mammalian genomic DNA 13 
extraction kit. For quantitative analysis of the attR and blasticidin-resistance gene copy numbers, real-14 
time PCR was performed with extracted DNA using a Light-Cycler instrument (Roche Diagnostics) 15 
and SYBR Premix Ex Taq (Takara Bio). The sequences of the primer sets used to determine the copy 16 
numbers of the attR and blasticidin-resistance gene were tcgagGCATCAAGCTAATTC + 17 
AGTACGCCCCCTATTGACG and gaagaccttcaacatctctcagc + atcttctcagtggcgacctc, respectively. A 18 
targeted integration product containing both the attR and blasticidin-resistance genes was obtained by 19 
the plasmid rescue method, and used to generate a standard curve. 20 
 21 
Analysis of integration sites by plasmid rescue 22 
To analyze phiC31 integrase-mediated integration sites, Hela-attPlex4R cells (5×104 cells) 23 
were transfected with 500 ng of pTargetB2(4x)-LexA-Rluc. Two days later, the cells were transfected 24 
with 500 ng of pCMV-int. XtremeGene9 was used for both transfections. From the next day, cells were 25 
cultured in medium containing 3 µg/ml blasticidin S for 18 days. DNA was isolated from these cells 26 
using a Genelute mammalian genomic DNA extraction kit, and digested using restriction enzyme NheI, 27 
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SpeI, and XbaI. After digestion by these restriction enzymes, the DNA was purified using a Genelute 1 
PCR Clean-up Kit (Sigma-Aldrich Japan) and ligated using a Rapid DNA Dephos & Ligation Kit 2 
(Roche Diagnostics) or Ligation convenience kit (Nippon Gene). The ligation products were used to 3 
transform E. coli Strain DH5α or HST08. pDNA was purified from blasticidin-resistant E coli using 4 
a PureYield plasmid Miniprep Kit. The nucleotide sequences of the pDNA were sequenced using a 5 
BigDye Terminator v3.1 Cycle Sequencing Kit (Life Technologies Japan, Tokyo, Japan) and 6 




Vector design to analyze inter-plasmid integration 11 
The phiC31 integrase-based vector system consists of two vector types. One is a donor 12 
vector that contains the attB sequence, and the other is a helper vector that expresses phiC31 integrase. 13 
PhiC31 integrase expressed by helper vectors integrates donor vectors into chromosomes.  14 
To enhance the site-specificity of phiC31 integrase-mediated integration, we designed the 15 
expression cassette of a dual DNA-binding protein which tethers the donor vector at the target 16 
sequence. The dual DNA-binding protein contains a Gal4 DNA-binding domain and LexA DNA-17 
binding domain, which recognize an upstream activation sequence (UAS) and a LexA operator 18 
sequence, respectively. Here, the LexA operator sequence was assumed to be a model of binding 19 
targets in chromosomes. Tethering of the donor vector by the dual DNA-binding protein limits phiC31 20 
integrase-mediated integration to the attP sites close to its target sequence (Fig. 1). pTargetB-LexA-21 
Rluc was constructed as a donor vector, in which both the expression cassettes of the DNA-binding 22 
protein and 4 copies of UAS were inserted in addition to the Renilla luciferase gene. The donor vector 23 
named pTargetB-NLS-Rluc was also constructed as a negative control. pTargetB-NLS-Rluc was the 24 
same as pTargetB-LexA-Rluc, except that it expressed a DNA-binding protein lacking the LexA DNA-25 
binding domain. pAttB-UAS-Rluc was another negative control donor vector, which had no 26 
expression cassette of DNA-binding protein. On the other hand, pCMV-int and pSV40-int were 27 
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constructed as helper vectors that express phiC31 integrase. To investigate whether the integration of 1 
pTargetB-LexA-Rluc is dependent on the distance between the target sequence for the DNA-binding 2 
protein and attP sequence, eight recipient vectors (i.e., pAttP-lex1~4F and 1~4R) having different 3 
attP-sequence orientations and different distances between the LexA operator and attP sequences were 4 
constructed (Fig. 2). 5 
 6 
Effect of the DNA-binding protein on the integration efficiency 7 
It was preliminarily investigated whether binding of the DNA-binding protein to the donor 8 
vector prevents phiC31 integrase from interacting with the donor vector. Following transfection of 9 
HEK293 cells with pTargetB-NLS-Rluc or pAttB-UAS-Rluc and with or without pCMV-int, 10 
sustainability of the gene expression of Rluc was evaluated as an indicator of integrations. When the 11 
effect of co-transfection with pCMV-int on the Rluc expression was evaluated on day 12, the sustained 12 
gene expression was enhanced by 2.32-fold and 1.45-fold in pTargetB-NLS-Rluc-transfected and 13 
pAttB-UAS-Rluc-transfected cells, respectively (Fig. 3). It should be remembered that the DNA-14 
binding protein could be expressed and associated with the donor vector in pTargetB-NLS-Rluc, but 15 
this was not the case in pAttB-UAS-Rluc. Nevertheless, the enhancement of sustained gene expression 16 
by phiC31 integrase was not lower in pTargetB-NLS-Rluc. This suggests that phiC31 integrase-17 
mediated integration was not inhibited even though the DNA-binding protein bound to the donor 18 
vectors. 19 
 20 
Integration site-specificity in inter-plasmid integration 21 
The effects of the DNA-binding protein on the integration site-specificity were investigated 22 
in an inter-plasmid integration assay. To avoid phiC31 integrase-mediated inter-plasmid integration 23 
during the amplification process in E. coli (Thorpe and Smith, 1998), pSV40-int was used as a helper 24 
vector instead of pCMV-int (Fig. 2). pSV40-int was chosen because, unlike the CMV promoter, the 25 
SV40 promoter does not express proteins in E. coli (Goussard et al., 2003). A preliminary experiment 26 




First, Hela cells were transfected simultaneously with pSV40-int as a helper vector, 2 
pTargeB-NLS-Rluc or pTargetB-LexA-Rluc as donor vectors, and pAttP-lex1~4F and 1~4R as 3 
recipient vectors. Two days later, DNA was extracted from these cells and transformed to E. coli. 4 
Taking into account that the inter-plasmid integration products contain blasticidin- and kanamycin-5 
resistance genes originated from donor and recipient vectors, respectively, transformed E. coli was 6 
selected by both blasticidin and kanamycin. The inter-plasmid integration products extracted from E. 7 
coli were digested with restriction enzymes and subjected to gel electrophoresis to determine to what 8 
extent each recipient vector was integrated. Figure 4a and b shows the percentages of integration into 9 
each recipient vector per total integration, and the ratio of the pTargetB-LexA-Rluc transfected group 10 
per the pTargetB-NLS-Rluc group, respectively. pTargetB-LexA-Rluc was designed to express a 11 
DNA-binding protein (i.e., the Gal4-LexA DNA-binding protein) that could bind to both the donor 12 
and recipient vectors, whereas pTargetB-NLS-Rluc expressed a protein that bound only to the donor 13 
vector. As shown in Fig. 4b, the percentage of integration into pAttP-lex4R, which has the smallest 14 
LexA-attP distance of 219 bp, was increased 4.5-fold in the pTargetB-LexA-Rluc group. 15 
 16 
Cell line establishment and vector construction for the analysis of chromosomal integration 17 
Prior to the evaluation of Gal4-LexA DNA-binding protein-enhanced integration site-18 
specificity in chromosomes, we established a stable cell line designated Hela-attPlex4R, in which both 19 
the attP and LexA operator sequences were chromosomally integrated. pAttP-lex4R was selected for 20 
the integration to establish Hela-attPlex4R, based on the results of the inter-plasmid integration assay 21 
(Fig. 4). At first, pAttP-lex4R was linearized and inserted into piggyBac transposon (hereafter pIR-22 
attPlex4R). Then, pIR-attPlex4R together with the piggyBac transposase expression vector pFerH-23 
PBTP were transfected into Hela cells to integrate the transposon containing the pAttP-lex4R-derived 24 
sequence into chromosomes (Fig. 5). Following selection, a stably integrated HeLa-attPlex4R cell 25 
clone was obtained and subjected to quantitative evaluation of chromosomal integration. Integration 26 
of attPlex4R sequences into the genome was evaluated with primers for neomycin-resistance gene in 27 
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the transposon, in reference with endogenous RNaseP gene. Real-time PCR analysis following 1 
extraction and digestion of genomic DNA revealed that the number of integrated copies was 15 copies 2 
per haploid genome in the Hela-attPlex4R clone. 3 
The Hela-attPlex4R thus established was transfected with pTargetB-NLS-Rluc or pTargetB-4 
LexA-Rluc with pCMV-int. Unfortunately, transfection with these vectors produced very few 5 
blasticidin-resistant cells (data not shown), despite the fact that the donor vectors contained the 6 
blasticidin-resistance gene. We redesigned the donor vector constructs so that they contained the attB 7 
sequence at a different position (Fig. 6a), taking into account a previous report that the location of the 8 
attB sequences in the donor vectors affects sustained gene expression by the phiC31 integrase-based 9 
vector system (Watanabe et al., 2011). To minimize the effect on blasticidin-resistance gene expression, 10 
the attB sequence was placed apart from the blasticidin-resistance gene in the newly developed donor 11 
vector construct pTargetB2-NLS-Rluc (Fig. 6a). As shown in Fig. 6b and c, transfection with 12 
pTargetB2-NLS-Rluc and pCMV-int provided significantly more blasticidin-resistant colonies than 13 
that with pTargetB-NLS-Rluc and pCMV-int. 14 
Considering that displacement of the attB sequence was effective for increased expression 15 
of the blasticidin-resistance gene, new donor vectors that expressed the Gal4-LexA DNA-binding 16 
protein were constructed and designated pTargetB2(0x)-LexA-Rluc, pTargetB2(4x)-LexA-Rluc, 17 
pTargetB2(18x)-LexA-Rluc, and pTargetB2(66x)-LexA-Rluc according to the number of UAS repeats 18 
(Fig. 6a). We expected that binding between the donor vectors and the Gal4-LexA DNA-binding 19 
protein would become more likely as the number of UAS increases. 20 
 21 
Integration site-specificity in chromosomal integration 22 
To evaluate the integration site-specificity in chromosomal integration, Hela-attPlex4R cells 23 
were transfected with pCMV-int and either pTargetB2-NLS-Rluc, pTargetB2(0x)-LexA-Rluc, 24 
pTargetB2(4x)-LexA-Rluc, pTargetB2(18x)-LexA-Rluc, or pTargetB2(66x)-LexA-Rluc. To allow the 25 
DNA-binding protein to be expressed and tether the donor vectors in advance, the cells were 26 
transfected with the donor vectors 1 or 2 days prior to transfection with pCMV-int. After transfections 27 
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of pCMV-int, the cells were subjected to blasticidin selection and extraction of genomic DNA. 1 
Quantitative PCR of genomic DNA was performed using forward and reverse primers designed to 2 
anneal to a sequence neighboring the LexA operator and a sequence inside a donor vector, respectively. 3 
These primers allowed us to count the copies of the donor vector integrated into the attP close to the 4 
LexA operator sequence (Fig. 7a). The copy number of total donor vectors was also evaluated as an 5 
internal control. As for the 1-day delay of pCMV-int transfection, the targeted integration efficiency 6 
of pTargetB2(4 ~ 18x)-LexA-Rluc was minimally higher than that of the negative controls (pTargetB2-7 
NLS-Rluc and pTargetB2(0x)-LexA-Rluc) (Fig. 7b). As for the 2 day delay of  pCMV-int 8 
transfection, the targeted integration efficiency of pTargetB2(4~18x)-LexA-Rluc was remarkably (up 9 
to 26-fold) higher than that of the negative controls (Fig. 7c). Unexpectedly, the targeted integration 10 
efficiencies of pTargetB2(66x)-LexA-Rluc were lower than that of pTargetB2(4~18x)-LexA-Rluc 11 
under both transfection conditions. 12 
 13 
Confirmation of targeted integration by sequencing analysis 14 
To confirm integration into the attP close to the LexA operator sequence, a plasmid rescue 15 
method was adopted. First, Hela-attPlex4R cells were transfected with pTargetB2(4x)-LexA-Rluc and, 16 
2 days later, with pCMV-int, and then selected by treatment with blasticidin. Secondly, genomic DNA 17 
was extracted from the cells, digested with restriction enzymes, ligated, and used for E. coli 18 
transformation. As pTargetB2(4x)-LexA-Rluc contains a blasticidin-resistance gene and E. coli 19 
replication origin, fragments of genomic DNA containing an insertion of pTargetB2(4x)-LexA-Rluc 20 
can be replicated in the presence of blasticidin. Of the obtained 2 clones of phiC31 integrase-mediated 21 
integration products, one is the targeted integration product (Table 1). Surprisingly, the other is 22 
integrated into pseudo-attP in pCMV-int. 23 
 24 
Discussion 25 
  26 
The present study was designed to enhance the integration site-specificity of phiC31 27 
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integrase-based vectors by tethering the donor vector to chromosomes with a target sequence-specific 1 
dual DNA-binding protein. Although the strategic concept has already been applied to Sleeping 2 
Beauty-based vectors (Ivics et al., 2007), we made some further improvements to adapt the method 3 
for phiC31 integrase-mediated integration. First, we incorporated an expression cassette for a dual 4 
DNA-binding protein in the donor vectors, instead of constructing donor vectors and the DNA-binding 5 
protein expression vectors separately. This guarantees the expression of the DNA-binding protein in 6 
cells transfected with the donor vectors. Secondly, we inserted multiple (4~66x) binding sequences 7 
into the donor vectors to increase the probability of binding the DNA-binding protein to the donor 8 
vectors. Thirdly, we transfected cells with the donor vectors in advance of transfection with the helper 9 
vector in order to ensure expression of the DNA-binding protein and tethering of the donor vectors at 10 
the target sequence of chromosomes prior to phiC31 integrase expression. 11 
Under the modified conditions, the donor vectors containing dual DNA-binding protein 12 
provided a higher integration site-specificity than their negative controls in both the inter-plasmid 13 
integration assay (Fig. 4b) and chromosomal integration assay (Fig. 7c). In previous studies using 14 
sequence-specific DNA-binding motifs, the fold increases of targeted chromosomal integration ranged 15 
from 2.0 to 9.9 (Ivics et al., 2007, Kettlun et al., 2011, Owens et al., 2012, Tan et al., 2006, Voigt et 16 
al., 2012). Even though our data cannot simply be compared with the previous data because of the 17 
differences in evaluation and analysis methods, a 26-fold increase in targeted chromosomal integration 18 
(Fig. 7c) would be considerably large. However, the percentage of the donor vector integrated into 19 
native attP (not pseudo-attP) neighboring the target sequence was not necessarily high (0.38% of tonal 20 
donor vectors; Fig. 7b). One reason for the low rate of targeted integration might be associated with 21 
the context of attP-surrounding sequence (Calos, 2006). The inter-plasmid integration assay showed 22 
that the integration efficiency of pTargetB-NLS-Rluc into pAttP-lex4R was lowest among all recipient 23 
vectors (Fig. 4a). This suggests that the context of pAttP-lex4R-derived surrounding sequences might 24 
not be suitable for phiC31 integrase-mediated integration. Therefore, if we select attP or pseudo-attP 25 
sequences with more suitable surrounding contexts, the targeted integration percentage may increase. 26 
In Hela-attPlex4R that was used for chromosomal integration assay, multiple target attP 27 
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sequences were inserted into the genome (15 copies per haploid genome). However, all the target attP 1 
sites might not necessarily be available for transgene expression due to their surrounding chromosomal 2 
contexts and epigenetic modifications. Selection of blasticidin-resistant cells could lead to 3 
underestimation of the degree of site-specific chromosomal integration of pTargetB2-LexA-Rluc, 4 
since it rules out integration to the target attP sites that do not allow the expression of the resistance 5 
marker. Taking together with the existence of pseudo-attP sites in some regions of the genome such 6 
as heterochromatin, it would be difficult to determine an exact efficiency count of targeted 7 
chromosomal integration. Thus, it should be noted that the present assay method of targeted integration 8 
simply allows relative comparison among the vector systems. 9 
In the chromosomal integration assay, delayed transfection of the helper vector after that of 10 
the donor vector transfections increased the difference between the pTargetB2(4~18x)-LexA-Rluc) 11 
and the negative controls (pTargetB2-NLS-Rluc and pTargetB2(0x)-LexA-Rluc) (Fig. 7b, c). These 12 
results suggest that the time-lag transfection provides an opportunity for the DNA-binding proteins to 13 
tether the donor vectors to the target sequences before phiC31 integrase-mediated integration. In 14 
addition to time-lag transfection, the use of chemical-regulatable gene expression systems is another 15 
option for producing an expression time-lag (Sharma et al., 2008 and Yen et al., 2004).  16 
Because of the simplicity of evaluation, the LexA operator sequence was selected as a target 17 
sequence of the DNA-binding protein by inserting it into chromosomes exogenously. However, when 18 
this targeted integration strategy is intended for practical applications such as gene therapies, the target 19 
sequences should be selected from native genomic sequences. To achieve safer chromosomal 20 
integration, pseudo-attP sequences in genomic safe harbors (Sadelain et al., 2012) should be selected 21 
as integration sites, and a specific DNA-binding motif should be customized so that it binds near the 22 
pseudo-attP sequences. In addition, it has been established that pseudo-attP sequences that can be 23 
recognized as substrates for phiC31 integrase exhibit certain variations in chromosomal context among 24 
cell types (Calos, 2006). Selection of different target sequences might thus be required depending on 25 
the cell types. 26 
The present targeted integration approach is theoretically applicable to other integrative 27 
14 
 
vector systems. Ivics et al. (2007) have shown that a LexA-SAFbox DNA-binding protein did not 1 
inhibit Sleeping Beauty-mediated integration, and during the preparation of this manuscript, Owens et 2 
al. (2013) reported targeted piggyBac integration by tethering of the donor vectors. As experienced 3 
with problem associated with the attB site (Fig. 6), the design of donor vectors appears to be important 4 
in targeted integration. As long as the vectors are carefully designed, the present targeted integration 5 
approach would be useful for other integrative vector systems, including Sleeping Beauty and 6 
piggyBac. 7 
In conclusion, we demonstrated by using phiC31 integrase-based integration systems that a 8 
multi-functional donor vector which expresses a sequence-specific dual DNA-binding protein that 9 
tethers itself to the target sequence and which has multiple sequences for binding of the protein works 10 
cooperatively with a helper vector when cells are subjected to both vector transfections separated by 11 
an appropriate time lag. We believe that the present study provides important information toward the 12 
achievement of site-specific transgene integration, and paves the way for more reliable gene therapies 13 
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Fig. 1 Schematic diagram of targeted integration using a sequence-specific DNA-binding 1 
protein and phiC31 integrase 2 
Gal4 and LexA DNA-binding domains of the Gal4-NLS-LexA DNA-binding protein bind to UAS and 3 
the LexA operator (the target sequence), respectively. Then, phiC31 integrase integrates the donor 4 
vector by recombining the attB and attP sequences. Because the donor vector is tethered to the target 5 
sequence, its integration site is restricted to the vicinity of the target sequence. 6 
 7 
Fig. 2 Vectors for targeted integration 8 
Vector construction. AmpR, ampicillin-resistance gene; attB, attB sequence for phiC31 integrase-9 
mediated recombination; attP, attP sequence for phiC31integrase-mediated recombination; BlastR, 10 
blasticidin-resistance gene; CMV, cytomegalovirus promoter; EM7, bacterial EM7 promoter; Gal4, 11 
Gal4 DNA-binding domain; hEF1, human elongation factor 1α promoter; LexA, LexA DNA-binding 12 
domain; NLS, nuclear localization signal; Rluc, Renilla luciferase gene; NeoR, neomycin-resistance 13 
gene; SV40, simian virus 40 promoter; ori, E. coli origin of replication; 4×UAS, four copies of 14 
upstream activating sequences; Kan/NeoR, kanamycin/neomycin-resistance gene; LexA operator, 15 
LexA operator sequence; SV40/BP, simian virus 40 promoter/Bacterial promoter. Each recipient 16 
vector (pAttP-lex1~4F and 1~4R) has one copy of attP at 6.5-6.6 (1F, 1R), 1.7-1.8 (2F, 2R), 0.6-0.7 17 
(3F, 3R), or 0.2-0.3 (4F, 4R) kb upstream, respectively, from LexA operator start point as indicated 18 
orientations. 19 
 20 
Fig. 3 Effect of DNA-binding proteins on phiC31 integrase-mediated sustained gene expression 21 
HEK293-lexluc cells (2x105 cells/well) were transfected with 500 ng of the indicated donor vector 22 
and 500 ng of pCMV-int or pcDNA3.1(+). The bars show the results for pAttB-UAS-Rluc and 23 
pcDNA3.1(+) (white), pAttB-UAS-Rluc and pCMV-int (hatched), pTargetB-NLS-Rluc and 24 
pcDNA3.1(+) (dotted), pTargetB-NLS-Rluc and pCMV-int (black), respectively. Renilla luciferase 25 
activities were measured at the indicated time points after transfection. Each value represents the mean 26 




Fig. 4 Effect of the DNA-binding protein on the integration site selection of phiC31 integrase in 2 
inter-plasmid integration 3 
Hela cells were transfected with pAttP-lex1F~4R (125 ng each), 1 µg pSV40-int (1 µg), and pTargetB-4 
LexA-Rluc or pTargetB-NLS-Rluc (1 µg). DNA extracted from Hela cells was subjected to E. coli 5 
transformation. Recombination products amplified in E. coli were analyzed by restriction digestion 6 
and agarose gel electrophoresis. Figure 4(a) shows the percentages of each inter-plasmid integration 7 
product per total inter-plasmid integration products. Open rectangles indicate inter-plasmid integration 8 
products of pTargetB-LexA-Rluc and each recipient vector. Closed squares indicate inter-plasmid 9 
integration products of pTargetB-NLS-Rluc and each recipient vector. Figure 4(b) represents the ratios 10 
of pTargetB-LexA-Rluc to pTargetB-NLS-Rluc in percentages of each inter-plasmid integration 11 
product. The abscissa indicates the distance between the LexA operator and attP sequences in each 12 
recipient vector. 13 
 14 
Fig. 5 Establishment of a stable cell line containing LexA operator and attP sequences in 15 
chromosomes 16 
To analyze integration site-specificity in a chromosomal context, LexA operator and attP sequences 17 
were integrated into the chromosomes of Hela cells by piggyBac transposase-mediated integration. 18 
AmpR, ampicillin-resistance gene; attP, attP sequence for phiC31integrase-mediated recombination; 19 
Kan/NeoR, kanamycin/neomycin-resistance gene; IR, piggyBac inverted repeat sequence for piggyBac 20 
transposase-mediated integration; LexA operator, LexA operator sequence; SV40/BP, simian virus 40 21 
promoter/bacterial promoter. 22 
 23 
Fig. 6 Colony-forming efficiency of pTargetB-NLS-Rluc and pTargetB2-NLS-Rluc 24 
Figure 6(a) shows the vector construction of pTargetB2-NLS-Rluc and pTargetB2(0~66x)-LexA-Rluc. 25 
attB, attB sequence for phiC31 integrase-mediated recombination; BlastR, blasticidin-resistance gene; 26 
CMV, cytomegalovirus promoter; Gal4, Gal4 DNA-binding domain; hEF1, human elongation factor 27 
22 
 
1α promoter; LexA, LexA DNA-binding domain; NLS, nuclear localization signal; Rluc, Renilla 1 
luciferase gene; SV40/EM7, simian virus 40 promoter/bacterial EM7 promoter; ori, E. coli origin of 2 
replication; 0~66xUAS, 0 to 66 copies of upstream activating sequences. Figure 6(b) shows the 3 
numbers of blasticidin-resistant colonies obtained following transfection with donor and helper 4 
vectors. Hela cells were transfected with 62.5 ng of the indicated donor vector and 187.5 ng of 5 
pcDNA3.1(+) (white bar) or pCMV-int (black bar). The number of colonies was counted by methylene 6 
blue staining after 2 weeks of selection with blasticidin S. Each value represents the mean + SD (n = 7 
4). The data were analyzed by Dunnett’s multiple-comparison test. Figure 6(c) shows photographs of 8 
colonies stained with methylene blue. 9 
 10 
Fig. 7 Effect of the DNA-binding protein on the integration site selection of phiC31 integrase in 11 
chromosomal integration 12 
Figure 7(a) shows the design of primers used to detect targeted integration. The forward and reverse 13 
primers are designed to anneal the nearby LexA operator sequence in chromosome and attB in the 14 
donor vectors, respectively. PCR amplified DNA only when targeted integration products are 15 
templates. Figure 7(b) and (c) represent percentages of the donor vector integrated into target attP per 16 
total donor vector remaining in the cells at 21 days after transfection. The helper vector (pCMV-int) 17 
was transfected 1 (b) or 2 (c) days after donor vector transfection. Each value represents the mean + 18 













Sequence and locations of phiC31 integrase-mediated integration of pTargetB2(4x)-LexA-
Rluc 
Sequences  Locations 
CGCGCCCGGGGAGCCCAATGAATCGGCCAACGCGCGGG
GAGAGGCGGTTTGCGTATTGGGC 
 320 bp upstream of 





 attP located 219 bp 
from LexA operator 
sequence 
Columns 1 and 2 show sequences of attR and flanked sequences and locations of integration 




 1. Construction of pIR-UAS-Rluc 
pIR-blastHGF was constructed as previously described (Nakanishi et al., 2010, Mol. Ther., 
18, 707-714). The UAS insert was created by PCR using the primers 
(AAATCGGAGTACTGTCCTCCGAGCGGAGTACTGTCCTCCG 
TCGCGACGGAGTACTGTCC, CTATATTACCCTGTTATCCCTAGCGTAACTCGGAGGA 
CAGTACTCCGGTCGGAGGACAGTACTCCGTCGCGA). To construct pIR-UAS-HGF, 
pIR-blastHGF was digested with the restriction enzyme SwaI, and ligated with the UAS insert. 
 The Rluc cDNA insert was amplified by PCR using pRL-SV40 (Promega, Tokyo, Japan) as a 
template and the primers (CACCGGTATGACTTCGAAAGTTTATGATCCAGA, 
GCTCTAGAATCGATGAATTATTGTTCATTTTTGAGAACTCG). The Rluc cDNA insert was 
digested with restriction enzymes AgeI and XbaI. To construct pIR-UASRluc, pIR-UASHGF was 
digested with restriction enzymes AgeI and NheI, and ligated with the digested Rluc cDNA insert. 
2. Construction of pTarget-NLS-Rluc 
The NLS insert was created by PCR using the primers (GAAGATCTGGCGATCGCC 
GATCCTAAGAAGAAGCGCAAGGTGGGCGACCCGAAAAAGAAACGCAAAGTT, 
TTCCAATGCATTGGCTGCAGGTTTAAACGGAATTCttctcACCGGTACCAACTTTGCGTTTCT
TTTTCGGG). To construct pET-NLS, the NLS insert and pET-42b (+) (Merk KGaA, Darmstadt, 
Germany) were digested with restriction enzymes BglII and PstI, and ligated. 
To obtain the DNA fragment containing NLS, pET-NLS was digested with restriction 
enzymes SgfI and PmeI. To construct pBIND-NLS, the DNA fragments containing NLS and 
pFN11A (BIND) (Promega) digested with SgfI and PmeI were ligated. 
pIR-UASRluc was digested with restriction enzymes SalI and MluI, and pBIND-NLS was 
digested with restriction enzymes BglII and FspI, respectively. To construct pTarget-NLS-Rluc-pre, 
these two digested pDNAs were blunted and ligated. 
Two DNA fragments were created by PCR using pTarget-NLS-Rluc-pre as a template and 
two primer sets (ATGACTTCGAAAGTTTATGATCCAgaacaa + 
AGGTTTAGTTCCTGGTGTACTTGAgggggatg, 
GGCCGGCCAATTCGCTAGAGGGCCCTATTCTATAGTGTCA + 
CCGCGGATCTCAGGTAGGCGCCGGTCA). To construct pTarget-NLS-Rluc, these two DNA 
fragments were ligated. 
3. Construction of pTarget-LexA-Rluc 
The LexA DNA-binding domain (LexA-DBD) insert was amplified by PCR using 
pLexA-C bait vector (Dualsystems Biotech, Schlieren, Switzerland) as a template and primers 
(TCCCCCCGGGcgaaccagttggatgaaagcgtta, CGGAATTCtcacagccagtcgccgttgc). pTarget-NLS-Rluc 
was digested with restriction enzymes AgeI and EcoRI, and the LexA-DBD insert was digested with 
restriction enzymes XmaI and EcoRI. To construct pTarget-LexA-Rluc, the digested 
pTarget-NLS-Rluc and LexA-DBD insert were ligated. 
4. Construction of pAttB-UAS-Rluc, pTargetB-NLS-Rluc, pTargetB-LexA-Rluc 
The attB insert was amplified by PCR using pORF-luc-attB as template and primers 
(CGCGCACGTACGAAACCGAAGCGAATTTCGAGGTG, 
CGCGCACGTACGGCCGCTCGAGGCATCAAGCTAAT). pIR-UAS-Rluc, pTarget-NLS-Rluc, 
pTarget-LexA-Rluc and the attB insert were digested with restriction enzyme BsiWI. To construct 
pAttB-UAS-Rluc, pTargetB-NLS-Rluc and pTargetB-LexA-Rluc, the digested attB insert was 
ligated with digested pIR-UAS-Rluc, pTarget-NLS-Rluc and pTarget-LexA-Rluc, respectively. 
5. Construction of pTargetB2(4x)-NLS-Rluc 
The attB insert was prepared as described above. The attB insert was phosphorylated, and 
ligated with pTarget-NLS-Rluc digested with restriction enzyme BmgBI. 
6. Construction of pTargetB2(4x)-LexA-Rluc 
pTargetB2(4x)-NLS-Rluc was digested with restriction enzymes BssHII and ApaLI, and 
the 2.8 kb DNA fragment containing the attB sequence was purified. pTarget-LexA-Rluc was 
digested with restriction enzymes BssHII and ApaLI, and the 5.1 kb DNA fragment containing the 
gene of the DNA-binding protein was purified. To obtain pTargetB2(4x)-LexA-Rluc, these purified 
DNA fragments were ligated. 
7. Construction of pTargetB2(6, 10, 18, 34 and 66x)-LexA-Rluc 
pTargetB2(4x)-LexA-Rluc was digested with restriction enzymes SwaI and AvrII, and the 
1.2 kb DNA fragment containing 4xUAS was purified. pTargetB2(4x)-LexA-Rluc was also digested 
with restriction enzymes NruI and AvrII, and the 6.7 kb DNA fragment containing 2xUAS was 
purified. To obtain pTargetB2(6x)-LexA-Rluc, these purified DNA fragments were ligated. 
pTargetB2(10, 18, 34 and 66x)-LexA-Rluc was constructed by repeating the same 
procedure. 
8. Construction of pTargetB2(0x)-LexA-Rluc 
pTargetB2(18x)-LexA-Rluc was digested with restriction enzymes SwaI and AvrII, and the 
6.7 kb DNA fragment containing no UAS was purified. pIR-blastHGF was also digested with 
restriction enzymes SwaI and AvrII, and the 1.1 kb DNA fragment was purified. To obtain 
pTargetB2(0x)-LexA-Rluc, these DNA fragments were ligated. 
9. Construction of pSV40-int 
pCMV-int (Addgene, Cambridge, MA, USA) was digested with restriction enzymes SpeI 
and NheI, and the DNA fragment containing the phiC31 integrase gene was purified. pRL-SV40 was 
digested with restriction enzymes NheI and XbaI, and the DNA fragment containing the SV40 
promoter was purified. To construct pSV40-int, these DNA fragments were ligated. 
10. Construction of pVITRO1-lexluc 
pCMV-luc was constructed as previously described (Nomura et al., 1999, Gene Ther., 6, 
121-129). The firefly luciferase gene flanked with the lexA operator sequence was amplified by PCR 
using pCMV-luc as a template and primers 
(CGGGATCCCTGTATATATATACAGATGGAAGACGCCAAAAACATAA, 
AAACGTACGCTAGTTACACGGCGATCTTTCC). To construct pVITRO1-lexluc, the PCR 
product and pVITRO1-neo-mcs (Invivogen, San Diego, CA, USA) were digested with restriction 
enzymes BamHI and BsiWI, and ligated. 
11. Construction of pAttP-DsRed express 
The whole DNA of pCMV-DsRed express (Takara Bio, Otsu, Japan) flanked with the attP 
sequence was amplified by PCR using pCMV-DsRed express as a template and primers 
(AGTTCTCTCAGTTGGGGGGCATTATGCCCAGTACATGACCTT, 
caaAGGTTACCCCAGTTGGGGcaggcgggccatttaccgtcatt). To construct pAttP-DsRed express, the 
PCR product was phosphorylated and self-ligated. 
12. Construction of pAttP-lex1F 
pAttP-DsRed express was digested with restriction enzymes ApaLI and NdeI. The DNA 
fragment containing the attP sequence was purified and blunted. pVITRO1-lexluc was digested with 
restriction enzyme PsiI and the DNA fragment containing the LexA operator sequence was purified. 
To construct pAttP-lex1F, the DNA fragments derived from pAttP-DsRed express and 
pVITRO1-lexluc were ligated. 
13. Construction of pAttP-lex1R 
pAttP-lex1F was digested with restriction enzymes ApaLI and NdeI. The DNA fragments 
were purified, blunted, and ligated. To obtain pAttP-lex1R, the pDNA with the attP sequence in a 
reverse orientation compared to pAttP-lex1F was selected from the ligation products. 
14. Construction of pAttP-lex2F, 2R, 3F, 3R, 4F, 4R 
To obtain pAttP0-lex, pAttP-lex1F was digested with restriction enzymes AfeI and ScaI, 
and the DNA fragment containing the LexA operator sequence was purified and self-ligated. 
pAttP-lex1F was digested with restriction enzymes AfeI and ScaI, and the DNA fragment containing 
the attP sequence was purified. To construct pAttP-lex2F, 2R, 3F, 3R, 4F and 4R, the DNA fragment 
was ligated with pAttP0-lex digested with restriction enzyme SnaBI, SmaI or BstZ17I, respectively. 
15. Construction of pIR-attPlex4Rt 
The DNA containing the 3’ and 5’ inverted repeat sequences of piggyBac transposon was 
amplified by PCR using p3E1.2 (a gift from Prof. Hajime Mori, Kyoto Institute of Technology, 
Kyoto, Japan) as a template, and primers (AGAACTACCCATTTTATTATATATTAGTCACGA, 
AATACAACATGACTGTTTTTAAAGTACAAAAT). To construct pIR-attPlex4R, pAttP-lex4R was 
digested with restriction enzyme HindIII, phosphorylated, and ligated with the PCR product 
containing inverted repeat sequences of piggyBac transposon.  
16. Construction of pVITRO1-neo-RnasePfragment 
The DNA containing a part of the RNaseP gene was amplified by PCR using the 
Hela-attPlex4R genome as a template and primers (AGATTTGGACCTGCGAGCG, 
GAGCGGCTGTCTCCACAAGT). To obtain pVITRO1-neo-RNasePfragment, the PCR product was 
purified, phosphorylated, and ligated with pVITRO1-neo-mcs digested with restriction enzyme 
BstZ17I. 
